Human Liver Organoid Platforms for MASH Drug Discovery: Evaluating Immunometabolic Fidelity, Pharmacological Predictivity, and Translational Readiness
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease characterised by steatosis, inflammation, hepatocellular injury and fibrosis. Human liver organoid platforms offer a controllable system for modelling selected MASH-related processes...